Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | FABP7 | O15540 | 1/20 | 0.52 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11240748 | 0.91 | FABP7 (0.49) | LMNACYP3A4ACHEFABP7FABP5 | |
| SCHEMBL26036690 | 0.85 | FABP7 (0.49) | LMNACYP3A4ACHEFABP7FABP5 | |
| SCHEMBL7679108 | 0.84 | LMNA (0.59) | LMNACYP3A4ACHEKMT2AMEN1 | |
| SCHEMBL28036637 | 0.82 | MEN1 (0.66) | LMNACYP3A4FABP7FABP5KMT2A | |
| SCHEMBL10547627 | 0.82 | CYP3A4 (0.58) | LMNACYP3A4ACHEKMT2AMEN1 | |
| SCHEMBL16953007 | 0.82 | LMNA (0.58) | LMNACYP3A4ACHEKMT2AMEN1 | |
| SCHEMBL30676498 | 0.82 | CYP3A4 (0.58) | LMNACYP3A4ACHEKMT2AMEN1 | |
| SCHEMBL21045001 | 0.81 | CYP19A1 (0.42) | LMNACYP3A4ACHEKMT2AMEN1 | |
| SCHEMBL15611000 | 0.81 | CYP3A4 (0.56) | LMNACYP3A4ACHEKMT2AMEN1 | |
| SCHEMBL14501378 | 0.81 | FABP7 (0.51) | FABP7FABP5KMT2AMEN1HAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-111517902-B | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2022-06-14 | — | — | CN | disclosed |
| US-10968163-B2 | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-04-06 | — | — | US | disclosed |
| CN-111517902-A | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2020-08-11 | — | — | CN | disclosed |
| WO-2020155595-A1 | AEROBIC OXIDATION SYSTEM CONTAINING SULFINIC ACID, SULFONIC ACID OR DERIVATIVES THEREOF AND PHOTOCATALYTIC OXIDATION METHOD THEREFOR | 清华大学 | 2020-08-06 | — | — | WO | disclosed |
| WO-2017156354-A1 | α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-09-14 | — | — | WO | disclosed |
| US-9575246-B2 | Prepolymer, curable material, coating composition, non-linear optical material, optical waveguide and light control device | ASAHI GLASS COMPANY, LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-2889684-A1 | PREPOLYMER, CURABLE MATERIAL, COATING COMPOSITION, NON-LINEAR OPTICAL MATERIAL, OPTICAL WAVEGUIDE AND LIGHT CONTROL DEVICE | Asahi Glass Company, Limited (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-20150153509-A1 | PREPOLYMER, CURABLE MATERIAL, COATING COMPOSITION, NON-LINEAR OPTICAL MATERIAL, OPTICAL WAVEGUIDE AND LIGHT CONTROL DEVICE | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| WO-2010007482-A2 | THIAZOLE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20080287705-A1 | METHOD OF PRODUCING ETHYNYL COMPOUND, METHOD OF HANDLING ETHYNYL COMPOUND, AND METHOD OF USING ASCORBIC ACID OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2008-11-20 | — | — | US | disclosed |
| US-20080287705-A1 | METHOD OF PRODUCING ETHYNYL COMPOUND, METHOD OF HANDLING ETHYNYL COMPOUND, AND METHOD OF USING ASCORBIC ACID OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2008-11-20 | — | — | US | disclosed |
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-07-31 | — | — | US | disclosed |
| EP-1939188-A1 | Oxa-and thiazole derivatives useful as antidiabetic and antiobesity agents | Bristol-Myers Squibb Company (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008062276-A2 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| WO-1991009066-A1 | HIGH CARBON RESINS AND FOAMS | HYPERION CATALYSIS INTERNATIONAL, INC. (US) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287705-A1 | METHOD OF PRODUCING ETHYNYL COMPOUND, METHOD OF HANDLING ETHYNYL COMPOUND, AND METHOD OF USING ASCORBIC ACID OR SALT THEREOF | KEAP1, CBR1, PROC | LMNA 1595/4885CYP3A4 214/4885ACHE 1660/4885 |
| US-20080182851-A1 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | SCD, SCD5, ACACA | LMNA 823/4885CYP3A4 1882/4885ACHE 3763/4885 |
| US-10968163-B2 | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | FABP1, FABP2, FABP4 | LMNA 1325/4885CYP3A4 1546/4885ACHE 2871/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | LMNA 320/4885CYP3A4 1682/4885ACHE 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.